Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...